Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna

S. Kojima, K. Matsumoto, K. Kato, T. Matsuyama, T. Sugihara, S. Minami, Y. Kodera, Y. Miyajima, I. Katayama, K. Horibe

Research output: Contribution to journalArticlepeer-review


Twenty-four patients with aplastic anemia (19 severe: 5 moderate) were treated with combined immunosuppression consisting of antithymocyte globulin (ATG: Lymphoser Berna, Swiss Serum and Vaccine Institute Berne) and high-dose methylprednisolone. Danazol or meptiostane was administered concurrently for at least 3 months. Three batches of ATG were used, two were not absorbed with thrombocytes and one was absorbed with thrombocytes for the prevention of thrombocytopenia. Nine of 20 evaluable patient (45%) had sustained improvement in hematopoiesis within 3 months of treatment. Nine of 14 patients (64%) showed a response to ATG without thrombocyte absorption, on the other hand, none of 6 patients responded to ATG with thrombocyte absorption. By life table analysis, the 3 year probability of survival was 81 +/- 27% after the combined immunosuppressive therapy. These results indicated that ATG therapy was very effective in Japanese patients with aplastic anemia.

Original languageEnglish
Pages (from-to)815-820
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Issue number7
Publication statusPublished - Jul 1993
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Medicine


Dive into the research topics of 'Treatment of aplastic anemia with antithymocyte globulin, Lymphoser Berna'. Together they form a unique fingerprint.

Cite this